We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Research Center Tackles Antimicrobial Drugs Challenge

By HospiMedica International staff writers
Posted on 28 Mar 2017
A new state-of-the-art research center aims to accelerate the development of new antibiotics by providing researchers and commercial companies with access to pharmacodynamics research expertise, facilities, and training.

Established by the University of Liverpool, the Liverpool School of Tropical Medicine, and North Bristol NHS Trust, the Centre for Antimicrobial Pharmacodynamics (CAP) will be aligned with antimicrobial resistance (AMR) accelerators in the United States and Europe, and will provide a local resource for around 20 UK and 90 global AMR companies.

CAP will provide a complete, integrated drug development package, including experimental models for invasive bacterial and fungal diseases, comprised of laboratory animal models, hollow fiber models of infection, and other well characterized in vitro models of infection; advanced pharmacokinetics and pharmacodynamics (PK-PD) mathematical modeling, including population pharmacokinetics, drug interaction modeling, antimicrobial resistance modeling, and Monte Carlo simulation; and bioanalysis run to GCP standards for laboratories.

Other services provided will include preclinical imaging to assess the distribution of small molecules in target tissues and organs; underpinning PK-PD studies in early phase clinical studies in Liverpool or in other clinical research facilities; training future generations of researchers; and running bespoke short courses, plus participation in expert workshops. More...
The CAP is also the first project to be announced as part of the newly launched Centre of Excellence in Infectious Diseases Research (CEIDR), a joint collaboration between the University of Liverpool and LSTM.

“Characterizing the preclinical and clinical pharmacokinetics and pharmacodynamics of anti-infective drugs is a relatively recent and mandatory regulatory requirement, which has created a bottleneck for AMR project progression because there is a lack of global skills and capacity to meet demand,” said Professor William Hope, MD, PhD, who will lead CAP. “The CAP will build on Liverpool’s existing strength in antimicrobial pharmacodynamics and therapeutics research to give scientists access to the skills and equipment they need to advance the development of new antibiotics.”

The new CAP facility will receive infrastructure funding from Innovate UK, an executive non-departmental public body of the UK government. In addition to the Innovate UK funding, the University of Liverpool will invest in new senior academic posts, while LSTM will contribute state-of-the-art laboratory space in the Liverpool Life Sciences Accelerator building, which is due to open in late 2017.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Ultrasound Needle Guidance System
SonoSite L25
New
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: New clinical guidance suggests treatments to prevent blood clots in CLTI patients after leg artery procedures (Photo courtesy of Shutterstock)

Stronger Blood Clot Prevention Measures Needed After Leg Artery Procedures in High-Risk Patients

Chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), significantly reduces blood flow to the legs and feet. Despite undergoing lower limb revascularization... Read more

Surgical Techniques

view channel
Image: The milli-spinner can shrink blood clots without rupturing them (Photo courtesy of Andrew Brodhead/Stanford)

New Technology More Than Doubles Success Rate for Blood Clot Removal

In cases of ischemic stroke, where a blood clot obstructs oxygen supply to the brain, time is critical. The faster the clot is removed and blood flow restored, the more brain tissue can be saved, improving... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.